Literature DB >> 18565021

Liver fat is reproducibly measured using computed tomography in the Framingham Heart Study.

Elizabeth K Speliotes1, Joseph M Massaro, Udo Hoffmann, Meredith C Foster, Dushyant V Sahani, Joel N Hirschhorn, Christopher J O'Donnell, Caroline S Fox.   

Abstract

BACKGROUND AND AIMS: Fatty liver is the hepatic manifestation of obesity, but community-based assessment of fatty liver among unselected patients is limited. We sought to determine the feasibility of and optimal protocol for quantifying fat content in the liver in the Framingham Heart Study using multidetector computed tomography (MDCT) scanning.
METHODS: Participants (n = 100, 49% women, mean age 59.4 years, mean body mass index 27.8 kg/m(2)) were drawn from the Framingham Heart Study cohort. Two readers measured the attenuation of the liver, spleen, paraspinal muscles, and an external standard from MDCT scans using multiple slices in chest and abdominal scans.
RESULTS: The mean measurement variation was larger within a single axial computed tomography (CT) slice than between multiple axial CT slices for the liver and spleen, whereas it was similar for the paraspinal muscles. Measurement variation in the liver, spleen, and paraspinal muscles was smaller in the abdomen than in the chest. Three versus six measures of attenuation in the liver and two versus three measures in the spleen gave reproducible measurements of tissue attenuation (intraclass correlation coefficient [ICCC] of 1 in the abdomen). Intra reader and interreader reproducibility (ICCC) of the liver-to-spleen ratio was 0.98 and 0.99, the liver-to-phantom ratio was 0.99 and 0.99, and the liver-to-muscle ratio was 0.93 and 0.86, respectively.
CONCLUSION: One cross-sectional slice is adequate to capture the majority of variance of fat content in the liver per individual. Abdominal scan measures as compared to chest scan measures of fat content in the liver are more precise. The measurement of fat content in the liver on MDCT scans is feasible and reproducible.

Entities:  

Mesh:

Year:  2008        PMID: 18565021      PMCID: PMC3057524          DOI: 10.1111/j.1440-1746.2008.05420.x

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  7 in total

1.  Protocol for measurement of liver fat by computed tomography.

Authors:  Lance E Davidson; Jennifer L Kuk; Timothy S Church; Robert Ross
Journal:  J Appl Physiol (1985)       Date:  2005-11-17

2.  Qualitative assessment of liver for fatty infiltration on contrast-enhanced CT: is muscle a better standard of reference than spleen?

Authors:  D M Panicek; C S Giess; L H Schwartz
Journal:  J Comput Assist Tomogr       Date:  1997 Sep-Oct       Impact factor: 1.826

3.  Noninvasive evaluation of graft steatosis in living donor liver transplantation.

Authors:  Minoru Iwasaki; Yasutsugu Takada; Michihiro Hayashi; Sachiko Minamiguchi; Hironori Haga; Yoji Maetani; Kazuhiro Fujii; Tetsuya Kiuchi; Koichi Tanaka
Journal:  Transplantation       Date:  2004-11-27       Impact factor: 4.939

4.  Prevalence of primary non-alcoholic fatty liver disease in a population-based study and its association with biochemical and anthropometric measures.

Authors:  Shira Zelber-Sagi; Dorit Nitzan-Kaluski; Zamir Halpern; Ran Oren
Journal:  Liver Int       Date:  2006-09       Impact factor: 5.828

Review 5.  The metabolic syndrome and type 2 diabetes: epidemiological figures and country specificities.

Authors:  Michel Procopiou; Jacques Philippe
Journal:  Cerebrovasc Dis       Date:  2005-11-07       Impact factor: 2.762

6.  Influence of endurance exercise training and sex on intramyocellular lipid and mitochondrial ultrastructure, substrate use, and mitochondrial enzyme activity.

Authors:  Mark A Tarnopolsky; Courtney D Rennie; Holly A Robertshaw; Stephanie N Fedak-Tarnopolsky; Michaela C Devries; Mazen J Hamadeh
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2006-11-09       Impact factor: 3.619

Review 7.  Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.

Authors:  Stephen A Harrison; Brent A Neuschwander-Tetri
Journal:  Clin Liver Dis       Date:  2004-11       Impact factor: 6.126

  7 in total
  53 in total

1.  Fatty liver is associated with dyslipidemia and dysglycemia independent of visceral fat: the Framingham Heart Study.

Authors:  Elizabeth K Speliotes; Joseph M Massaro; Udo Hoffmann; Ramachandran S Vasan; James B Meigs; Dushyant V Sahani; Joel N Hirschhorn; Christopher J O'Donnell; Caroline S Fox
Journal:  Hepatology       Date:  2010-06       Impact factor: 17.425

2.  Dimethylguanidino valeric acid is a marker of liver fat and predicts diabetes.

Authors:  John F O'Sullivan; Jordan E Morningstar; Qiong Yang; Baohui Zheng; Yan Gao; Sarah Jeanfavre; Justin Scott; Celine Fernandez; Hui Zheng; Sean O'Connor; Paul Cohen; Ramachandran S Vasan; Michelle T Long; James G Wilson; Olle Melander; Thomas J Wang; Caroline Fox; Randall T Peterson; Clary B Clish; Kathleen E Corey; Robert E Gerszten
Journal:  J Clin Invest       Date:  2017-10-30       Impact factor: 14.808

3.  Independent markers of nonalcoholic fatty liver disease in a gentrifying population-based Chinese cohort.

Authors:  Xianghai Zhou; Yufeng Li; Xiuying Zhang; Ying Ying Guan; Yindra Puentes; Fang Zhang; Elizabeth K Speliotes; Linong Ji
Journal:  Diabetes Metab Res Rev       Date:  2019-04-17       Impact factor: 4.876

4.  Comparison of new and conventional versions of model-based iterative reconstruction in reduced-dose computed tomography for diagnosis of hepatic steatosis.

Authors:  Koichiro Yasaka; Masaki Katsura; Jiro Sato; Masaaki Akahane; Izuru Matsuda; Kuni Ohtomo
Journal:  Jpn J Radiol       Date:  2016-02-23       Impact factor: 2.374

5.  Ethnic and sex differences in fatty liver on cardiac computed tomography: the multi-ethnic study of atherosclerosis.

Authors:  Rajesh Tota-Maharaj; Michael J Blaha; Irfan Zeb; Ronit Katz; Ron Blankstein; Roger S Blumenthal; Matthew J Budoff; Khurram Nasir
Journal:  Mayo Clin Proc       Date:  2014-03-07       Impact factor: 7.616

6.  Relations of liver fat with prevalent and incident chronic kidney disease in the Framingham Heart Study: A secondary analysis.

Authors:  Robert M Wilechansky; Alison Pedley; Joseph M Massaro; Udo Hoffmann; Emelia J Benjamin; Michelle T Long
Journal:  Liver Int       Date:  2019-05-24       Impact factor: 5.828

7.  Preoperative computed tomography measurements of pancreatic steatosis and visceral fat: prognostic markers for dissemination and lethality of pancreatic adenocarcinoma.

Authors:  Abhishek Mathur; Jonathan Hernandez; Fawad Shaheen; Miloni Shroff; Sujat Dahal; Connor Morton; Thomas Farrior; Raj Kedar; Alexander Rosemurgy
Journal:  HPB (Oxford)       Date:  2011-06       Impact factor: 3.647

8.  Assessment of liver fat in an obese patient population using noncontrast CT fat percent index.

Authors:  Ali F Jon; Ahmad R Cheema; Atif N Khan; Vassilios Raptopoulos; Thomas Hauser; Imad Nasser; Francine K Welty; Andrew Karellas; Melvin E Clouse
Journal:  Clin Imaging       Date:  2014-01-17       Impact factor: 1.605

9.  A simple clinical model predicts incident hepatic steatosis in a community-based cohort: The Framingham Heart Study.

Authors:  Michelle T Long; Alison Pedley; Joseph M Massaro; Udo Hoffmann; Jiantao Ma; Rohit Loomba; Raymond T Chung; Emelia J Benjamin
Journal:  Liver Int       Date:  2018-03-12       Impact factor: 5.828

10.  Comparison of coronary plaque subtypes in male and female patients using 320-row MDCTA.

Authors:  Faisal Khosa; Atif N Khan; Khurram Nasir; Arash Bedayat; Zehra Malik; Ali F Jon; Ahmad R Cheema; Melvin E Clouse; Francine K Welty
Journal:  Atherosclerosis       Date:  2012-12-13       Impact factor: 5.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.